Curasight

During the conference, Curasight management will hold scheduled one-to-one meetings with international healthcare investors and industry representatives to discuss the Company's clinical development programs, strategic priorities and potential partnering opportunities.

The meetings will provide an opportunity to highlight Curasight's differentiated uPAR-targeted portfolio, comprising uTREAT® for radioligand therapy and uTRACE® for PET imaging and diagnostics. Discussions will focus on the Company's lead glioblastoma therapeutic program, its ongoing Phase 2 prostate cancer diagnostic program and the development of next-generation uPAR-targeting ligands designed to support radioligand therapy across multiple solid tumor indications.

About Curasight A/S

Curasight is a clinical-stage radiopharmaceutical company developing uPAR-targeted radiopharmaceuticals for cancer therapy and diagnostic imaging. uPAR is a cell-surface target associated with aggressive tumor biology and has been clinically characterized using PET imaging in more than 500 patients across nine clinical studies and eight tumor types.

Curasight's portfolio comprises uTREAT® for radioligand therapy and uTRACE® for PET imaging and diagnostics. Its lead therapeutic program targets glioblastoma, while its prostate cancer diagnostic program is in Phase 2 and partnered with Curium. The Company is also advancing next-generation uPAR-targeting ligands designed for use with alpha- and beta-emitting radionuclides, supporting potential therapeutic applications across multiple solid tumors.